50
Omalizumab and Severe Alergic Asthma : Assessment after 1 Year of Treatment
Saturday, March 5, 2016
South Exhibit Hall H (Convention Center)
Rita Aguiar, MD, Ana M. Mendes, MD, Ana Célia Costa, MSc, Fatima Duarte, MD, Estrella Alonso, Anabela Lopes, MD, Elisa Pedro, MD, Manuel Pereira-Barbosa
Rationale: Omalizumab is associated with improvement in asthma symptoms and quality of life in patients with severe asthma. Our aim is to evaluate clinical improvement and quality of life of patients treated with omalizumab in our Department.

Methods: Patients with severe asthma under Omalizumab treatment for 12 months were included. They signed informed consent and responded to the questionnaires: ACT (Asthma Control Test), CARAT (Control Test Asthma and Allergic Rhinitis) and AQLQ (Quality of Life Questionnaire on Asthma). FEV1 was evaluated at T0 and T12. Data were analyzed using SPSS®version 17, p-value <0.05 was considered significant.

Results: 31 patients were included: average age of 36 years-old, 22 females, all non-smokers. At T12, 16 patients (51.6%) obtained a ACT score of 25 (fully controlled asthma); 13 patients (42%) a CARAT score of 24 and 22 pts (71%) a score> 8 in the sum of the items 1-4 of CARAT (good control of upper airways). The AQLQ average score was 6.4 (high quality of life) with symptoms domains presenting the lowest scores. Inferential analysis showed that quality of life of patients was significantly influenced by the level of asthma control.

16 patients (51.6%) showed an increase in FEV1 and 15 maintained overlapping values at T0 and T12. FEV1 at T0 was an average of 1.96 ± 0.80 L/min, 73%of predicted and 2.10 ± 0.82 at T12, 77% of predicted (p = 0.04).

Conclusions: Our data showed that omalizumab is associated with a good asthma control, improvement in lung function and high quality of life.